-
公开(公告)号:US07351708B2
公开(公告)日:2008-04-01
申请号:US11634563
申请日:2006-12-06
申请人: Matthias Nettekoven , Olivier Roche
发明人: Matthias Nettekoven , Olivier Roche
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/55 , C07D487/04
CPC分类号: C07D471/04
摘要: The present invention relates to compounds of formula I wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译: 本发明涉及式I化合物,其中R 1至R 4如在说明书和权利要求书中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号:US20130217729A1
公开(公告)日:2013-08-22
申请号:US13855470
申请日:2013-04-02
IPC分类号: C07D401/06
CPC分类号: C07D401/06 , C07D211/96
摘要: The present invention relates to piperidine sulphonamide derivatives of formula wherein Ar1, Ar2, R1, R2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula I are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.
-
公开(公告)号:US08202888B2
公开(公告)日:2012-06-19
申请号:US12365911
申请日:2009-02-05
IPC分类号: A61K31/454 , C07D401/06
CPC分类号: C07D401/06 , C07D211/96
摘要: The present invention relates to piperidine sulphonamide derivatives of formula wherein Ar1, Ar2, R1, R2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula I are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.
摘要翻译: 本发明涉及下式的哌啶磺酰胺衍生物其中Ar 1,Ar 2,R 1,R 2,m和n如说明书和权利要求中所定义,或其药学上合适的酸加成盐。 式I化合物是食欲蛋白受体拮抗剂,相关化合物可用于治疗睡眠呼吸暂停,发作性睡病,失眠,睡眠,夜间综合征,昼夜节律障碍或与神经疾病相关的睡眠障碍。
-
公开(公告)号:US08017773B2
公开(公告)日:2011-09-13
申请号:US12689064
申请日:2010-01-18
申请人: Matthias Nettekoven , Olivier Roche
发明人: Matthias Nettekoven , Olivier Roche
IPC分类号: C07D241/04 , A61K31/4965
CPC分类号: C07D295/185 , C07D213/71 , C07D233/84 , C07D241/18 , C07D261/10 , C07D277/36 , C07D295/22 , C07D333/34
摘要: The present invention relates to compounds of formula I wherein R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译: 本发明涉及式I化合物,其中R 1至R 3如说明书和权利要求中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号:US20100120791A1
公开(公告)日:2010-05-13
申请号:US12689064
申请日:2010-01-18
申请人: Matthias Nettekoven , Olivier Roche
发明人: Matthias Nettekoven , Olivier Roche
IPC分类号: A61K31/4965 , C07D241/04
CPC分类号: C07D295/185 , C07D213/71 , C07D233/84 , C07D241/18 , C07D261/10 , C07D277/36 , C07D295/22 , C07D333/34
摘要: The present invention relates to compounds of formula I wherein R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译: 本发明涉及式I化合物,其中R 1至R 3如说明书和权利要求中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号:US20090312314A1
公开(公告)日:2009-12-17
申请号:US12481627
申请日:2009-06-10
IPC分类号: A61K31/536 , C07D213/56 , A61K31/44 , C07D401/02 , A61K31/4439 , A61K31/444 , C07D277/20 , A61K31/426 , C07D215/38 , A61K31/47 , C07D265/36 , A61P25/00
CPC分类号: C07D213/40 , C07D213/56 , C07D213/75 , C07D215/38 , C07D231/40 , C07D261/08 , C07D277/46 , C07D333/20 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要: The present invention is concerned with novel sulfonamides of formula wherein R1, R2, R3, R4, R5, Ar, Ar1, Ar2, n, o and p are as described in the description and claims. The compounds are orexin receptor antagonists that may be useful in the treatment of disorders, in which orexin pathways are involved.
摘要翻译: 本发明涉及下列新型磺酰胺,其中R1,R2,R3,R4,R5,Ar,Ar1,Ar2,n,o和p如说明书和权利要求中所述。 这些化合物是食欲素受体拮抗剂,其可用于治疗其中涉及食欲素途径的病症。
-
公开(公告)号:US07557108B2
公开(公告)日:2009-07-07
申请号:US12018284
申请日:2008-01-23
申请人: Matthias Nettekoven , Olivier Roche
发明人: Matthias Nettekoven , Olivier Roche
IPC分类号: A61K31/496 , C07D209/08 , C07D235/06
CPC分类号: C07D209/08 , C07D235/06
摘要: The present invention relates to compounds of formula I wherein one of R1 and R2 is hydrogen and the other one is and wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译: 本发明涉及式I化合物,其中R 1和R 2之一是氢,另一个是且其中A和R 1至R 4如说明书和权利要求中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号:US07514433B2
公开(公告)日:2009-04-07
申请号:US11880083
申请日:2007-07-19
申请人: Matthias Nettekoven , Olivier Roche
发明人: Matthias Nettekoven , Olivier Roche
IPC分类号: A61K31/5377 , A61K31/496 , C07D401/14 , C07D413/14
CPC分类号: C07D403/06 , C07D401/14 , C07D413/14
摘要: The present invention relates to the compounds of formula I: wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译: 本发明涉及式I化合物:其中R 1至R 4如说明书和权利要求书中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号:US20080249125A1
公开(公告)日:2008-10-09
申请号:US12056324
申请日:2008-03-27
申请人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
发明人: Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
IPC分类号: A61K31/437 , C07D471/02 , C07D513/02 , A61K31/4365 , A61K31/4375 , A61P25/00
CPC分类号: C07D471/04 , C07D495/04
摘要: The present invention relates to compounds of formula wherein R1, R2, R3, and R4 are as defined herein and hetaryl is a one or two ring-membered heteroaromatic ring system, connected to the carbon atoms of the piperidine group selected from the group consisting of or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders in which orexin pathways are involved, like sleep disorders.
摘要翻译: 本发明涉及下式的化合物其中R 1,R 2,R 3和R 4是 如本文所定义,杂芳基是与哌啶基的碳原子连接的一个或两个环 - 元杂芳族环系统,所述哌啶基团选自由药学上合适的酸加成盐,光学纯对映异构体,外消旋体或非对映体混合物组成的组。 这些化合物是食欲素受体拮抗剂,并且可用于治疗涉及食欲素途径的疾病,例如睡眠障碍。
-
50.
公开(公告)号:US20080188486A1
公开(公告)日:2008-08-07
申请号:US12018284
申请日:2008-01-23
申请人: Matthias Nettekoven , Olivier Roche
发明人: Matthias Nettekoven , Olivier Roche
IPC分类号: A61K31/496 , C07D295/00 , A61P3/04
CPC分类号: C07D209/08 , C07D235/06
摘要: The present invention relates to compounds of formula I wherein one of R1 and R2 is hydrogen and the other one is and wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译: 本发明涉及式I化合物,其中R 1和R 2之一是氢,另一个是且其中A和R 1, R 4和R 4如在说明书和权利要求书中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
-
-
-
-
-
-
-
-